Johnson & Johnson said federal drug regulators have not approved its application to market a once-per-day version of its HIV pill Prezista and wants more information. The company said it is reviewing the Food and Drug Administration's response to its marketing application for an 800-milligram Prezista pill, and it plans to respond as quickly as possible. Johnson & Johnson said it does not expect to have to run any new clinical trials of the drug.
